J&J has tough third quarter
This article was originally published in The Rose Sheet
Executive Summary
Firm's U.S. skin-care business declined 15.9% on an operational basis and oral care fell 12.3% over a "disappointing" third quarter, Johnson & Johnson announces Oct. 19. Net sales for the U.S. consumer division decreased 24.5% in the quarter to $1.28 billion, hampered by unavailable OTC drugs included in the firm's April recall of liquid pediatric products. Worldwide, consumer sales fell 10.6% year-over-year to $3.57 billion. Several bright spots in the quarter included "positive" results of the Dabao Chinese skin-care line and the launch of Listerine Zero alcohol-free mouthwash, firm says. J&J's worldwide net sales dipped 0.7% to $14.98 billion for the quarter and net earnings increased 2.2% to $3.42 billion
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.